RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults

被引：131

作者：

Wen, Patrick Y. ^{[1
,2
]}

van den Bent, Martin ^{[3
]}

Youssef, Gilbert ^{[1
,2
]}

Cloughesy, Timothy F. ^{[4
]}

Ellingson, Benjamin M. ^{[5
]}

Weller, Michael ^{[6
,7
]}

Galanis, Evanthia ^{[8
]}

Barboriak, Daniel P. ^{[9
]}

de Groot, John ^{[10
]}

Gilbert, Mark R. ^{[11
]}

Huang, Raymond ^{[2
,12
]}

Lassman, Andrew B. ^{[13
,14
,15
]}

Mehta, Minesh ^{[16
]}

Molinaro, Annette M. ^{[17
]}

Preusser, Matthias ^{[18
]}

Rahman, Rifaquat ^{[19
]}

Shankar, Lalitha K. ^{[20
]}

Stupp, Roger ^{[21
,22
,23
,24
]}

Villanueva-Meyer, Javier E. ^{[25
,26
]}

Wick, Wolfgang ^{[27
,28
]}

Macdonald, David R. ^{[29
,30
]}

Reardon, David A. ^{[1
,2
]}

Vogelbaum, Michael A. ^{[31
,32
]}

Chang, Susan M. ^{[10
]}

机构：

[1] Dana Farber Canc Inst, Ctr Neurooncol, 450 Brookline Ave, Boston, MA 02215 USA

[2] Harvard Med Sch, Boston, MA USA

[3] Erasmus MC Canc Inst, Dept Neurooncol, Rotterdam, Netherlands

[4] Univ Calif Los Angeles, David Geffen Sch Med, UCLA Brain Tumor Program, Los Angeles, CA USA

[5] Univ Calif Los Angeles, David Geffen Sch Med, Dept Radiol Sci, UCLA Brain Tumor Imaging Lab, Los Angeles, CA USA

[6] Univ Hosp Zurich, Dept Neurol, Zurich, Switzerland

[7] Univ Zurich, Zurich, Switzerland

[8] Mayo Clin, Dept Oncol, Rochester, MN USA

[9] Duke Univ, Med Ctr, Dept Radiol, Durham, NC USA

[10] Univ Calif San Francisco, Dept Neurosurg, Div Neurooncol, San Francisco, CA USA

[11] NCI, Neurooncol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA

[12] Brigham & Womens Hosp, Dept Radiol, Div Neuroradiol, Boston, MA USA

[13] Columbia Univ, Vagelos Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr, Dept Neurol,Div Neuroradiol, New York, NY USA

[14] Columbia Univ, Irving Inst Clin & Translat Res, Vagelos Coll Phys & Surg, New York, NY USA

[15] New York Presbyterian Hosp, New York, NY USA

[16] Miami Canc Inst, Miami, FL USA

[17] Univ Calif San Francisco, Dept Neurol Surg, Div Biomed Stat & Informat, San Francisco, CA USA

[18] Med Univ Vienna, Dept Med 1, Div Oncol, Vienna, Austria

[19] Brigham & Womens Hosp, Dept Radiat Oncol, Boston, MA USA

[20] NCI, Clin Trials Branch, Canc Imaging Program, NIH, Bethesda, MD USA

[21] Northwestern Univ, Malnati Brain Tumor Inst, Lurie Comprehens Canc Ctr, Chicago, IL USA

[22] Northwestern Univ, Dept Neurol Surg, Chicago, IL USA

[23] Northwestern Univ, Dept Neurol, Chicago, IL USA

[24] Northwestern Univ, Div Hematol Oncol, Chicago, IL USA

[25] Univ Calif San Francisco, Dept Radiol, San Francisco, CA USA

[26] Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA USA

[27] Heidelberg Univ Hosp, Dept Neurol, Heidelberg, Germany

[28] German Canc Res Ctr, ClinicalCooperat Unit Neurooncol, German Canc Consortium DKTK, Heidelberg, Germany

[29] Western Univ, Dept Clin Neurol Sci, London, ON, Canada

[30] Western Univ, Dept Oncol, London, ON, Canada

[31] H Lee Moffitt Canc Ctr & Res Inst, Dept Neurooncol, Tampa, FL USA

[32] H Lee Moffitt Canc Ctr & Res Inst, Dept Neurosurg, Tampa, FL USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 33期

关键词：

MALIGNANT GLIOMA; GLIOBLASTOMA; PSEUDOPROGRESSION; PROGRESSION; RECOMMENDATIONS; RECIST; PET;

D O I：

10.1200/JCO.23.01059

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PURPOSEThe Response Assessment in Neuro-Oncology (RANO) criteria for high-grade gliomas (RANO-HGG) and low-grade gliomas (RANO-LGG) were developed to improve reliability of response assessment in glioma trials. Over time, some limitations of these criteria were identified, and challenges emerged regarding integrating features of the modified RANO (mRANO) or the immunotherapy RANO (iRANO) criteria.METHODSInformed by data from studies evaluating the different criteria, updates to the RANO criteria are proposed (RANO 2.0).RESULTSWe recommend a standard set of criteria for both high- and low-grade gliomas, to be used for all trials regardless of the treatment modalities being evaluated. In the newly diagnosed setting, the postradiotherapy magnetic resonance imaging (MRI), rather than the postsurgical MRI, will be used as the baseline for comparison with subsequent scans. Since the incidence of pseudoprogression is high in the 12 weeks after radiotherapy, continuation of treatment and confirmation of progression during this period with a repeat MRI, or histopathologic evidence of unequivocal recurrent tumor, are required to define tumor progression. However, confirmation scans are not mandatory after this period nor for the evaluation of treatment for recurrent tumors. For treatments with a high likelihood of pseudoprogression, mandatory confirmation of progression with a repeat MRI is highly recommended. The primary measurement remains the maximum cross-sectional area of tumor (two-dimensional) but volumetric measurements are an option. For IDH wild-type glioblastoma, the nonenhancing disease will no longer be evaluated except when assessing response to antiangiogenic agents. In IDH-mutated tumors with a significant nonenhancing component, clinical trials may require evaluating both the enhancing and nonenhancing tumor components for response assessment.CONCLUSIONThe revised RANO 2.0 criteria refine response assessment in gliomas.

引用

页码：5189 / +

页数：15

共 50 条

[21] Evaluation of the Implementation of the Response Assessment in Neuro-Oncology Criteria in the HERBY Trial of Pediatric Patients with Newly Diagnosed High-Grade Gliomas
Rodriguez, D.
Chambers, T.
Warmuth-Metz, M.
Aliaga, E. Sanchez
Warren, D.
Calmon, R.
Hargrave, D.
Garcia, J.
Vassal, G.
Grill, J.
Zahlmann, G.
Morgan, P. S.
Jaspan, T.
AMERICAN JOURNAL OF NEURORADIOLOGY, 2019, 40 (03) : 568 - 575
[22] VOLUMETRY-BASED RESPONSE CHARACTERIZATION OF RECURRENT PEDIATRIC LOW-GRADE GLIOMAS IN PNOC CLINICAL NEURO-ONCOLOGY TRIALS
von Reppert, Marc
Lin, MingDe
Bousabarah, Khaled
Familiar, Ariana
Velasco, Ryan
Waanders, Angela
Vossough, Arastoo
Haddock, Amanda
Nicolaides, Theodore
Swanson, Kristin
Kazerooni, Anahita
Kline, Cassie
Nabavizadeh, Ali
Haas-Kogan, Daphne
Prados, Michael
Rubin, Joshua
Mueller, Sabine
Aboian, Mariam
NEURO-ONCOLOGY, 2022, 24 : 100 - 100
[23] Application of Novel Response/Progression Measures for Surgically Delivered Therapies for Gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group
Vogelbaum, Michael A.
Jost, Sarah
Aghi, Manish K.
Heimberger, Amy B.
Sampson, John H.
Wen, Patrick Y.
Macdonald, David R.
Van den Bent, Martin J.
Chang, Susan M.
NEUROSURGERY, 2012, 70 (01) : 234 - 243
[24] RESPONSE ASSESSMENT IN PEDIATRIC LOW-GRADE GLIOMA: RECOMMENDATIONS FROM THE RESPONSE ASSESSMENT IN PEDIATRIC NEURO-ONCOLOGY (RAPNO) WORKING GROUP
Fangusaro, Jason
Witt, Olas
Driever, Pablo Hernaiz
Bag, Asim
de Blank, Peter
Kadom, Nadja
Kilburn, Lindsay
Lober, Robert
Robison, Nathan
Fisher, Michael
Packer, Roger
Poussaint, Tina Young
Papusha, Ludmila
Avula, Shivaram
Brandes, Alba
Bouffet, Eric
Bowers, Daniel
Artemov, Anton
Chintagumpala, Murali
Zurakowski, David
van den Bent, Martin
Bison, Brigitte
Yeom, Kristen
Taal, Walter
Warren, Katherine
NEURO-ONCOLOGY, 2020, 22 : 355 - 355
[25] Response assessment in paediatric low-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group
Fangusaro, Jason
Witt, Olaf
Driever, Pablo Hernaiz
Bag, Asim K.
de Blank, Peter
Kadom, Nadja
Kilburn, Lindsay
Lober, Robert M.
Robison, Nathan J.
Fisher, Michael J.
Packer, Roger J.
Poussaint, Tina Young
Papusha, Ludmila
Avula, Shivaram
Brandes, Alba A.
Bouffet, Eric
Bowers, Daniel
Artemov, Anton
Chintagumpala, Murali
Zurakowski, David
van den Bent, Martin
Bison, Brigitte
Yeom, Kristen W.
Taal, Walter
Warren, Katherine E.
LANCET ONCOLOGY, 2020, 21 (06): : E305 - E316
[26] Response Assessment in Neuro-Oncology Criteria and Clinical Endpoints
Huang, Raymond Y.
Wen, Patrick Y.
MAGNETIC RESONANCE IMAGING CLINICS OF NORTH AMERICA, 2016, 24 (04) : 705 - +
[27] Resecting diffuse low-grade gliomas to the boundaries of brain functions: a new concept in surgical neuro-oncology
Duffau, H.
JOURNAL OF NEUROSURGICAL SCIENCES, 2015, 59 (04) : 361 - 371
[28] Response Assessment in Neuro-Oncology Criteria for Gliomas: Practical Approach Using Conventional and Advanced Techniques
Leao, D. J.
Craig, P. G.
Godoy, L. F.
Leite, C. C.
Policeni, B.
AMERICAN JOURNAL OF NEURORADIOLOGY, 2020, 41 (01) : 10 - 20
[29] Application of Novel Response/Progression Measures for Surgically Delivered Therapies for Gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group COMMENT
Chiocca, E. Antonio
NEUROSURGERY, 2012, 70 (01) : 243 - 244
[30] Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas
Albert, Nathalie L.
Weller, Michael
Suchorska, Bogdana
Galldiks, Norbert
Soffietti, Riccardo
Kim, Michelle M.
La Fougere, Christian
Pope, Whitney
Law, Ian
Arbizu, Javier
Chamberlain, Marc C.
Vogelbaum, Michael
Ellingson, Ben M.
Tonn, Joerg C.
NEURO-ONCOLOGY, 2016, 18 (09) : 1199 - 1208

← 1 2 3 4 5 →